Insulet (Nasdaq:PODD) announced the groundbreaking of its new Omnipod manufacturing facility in Malaysia.
Acton, Massachusetts–based Insulet’s Johor Bahru, Malaysia-based manufacturing facility will produce its Omnipod automated insulin delivery system and strengthen the company’s global manufacturing capabilities.
The facility will include approximately 400,000 square feet of manufacturing space, with Insulet planning to invest approximately $200 million over five years and hire more than 500 full-time employees once the facility operates at full capacity, according to a news release.
Insulet also has plans to source environmentally responsible and resource-efficient materials for the new facility, with an architectural design that features sustainable elements that qualify for Green Building Initiative (GBI) and Leadership in Energy and Environmental Design (LEED) certification. The company said its regional sourcing strategy includes the use of local suppliers for component parts.
“We are taking an important step to further diversify globally and ensure our valued customers continue to have uninterrupted access to our life-changing products,” Insulet EVP and COO Chuck Alpuche said in the release. “This new Malaysian factory will help support our fast-paced growth, robust innovation pipeline, and global expansion.”
Insulet expects the Malaysia manufacturing facility to be operational by the middle of 2024.
“We are pleased to welcome Insulet to Malaysia as the medical device company expands their manufacturing capabilities,” Johor State Investment, Trade and Consumer Affairs Committee Chair Lee Ting Han said. “This project validates Johor’s attractiveness as a top international investment destination. We believe this new facility will play an important role in the development of the State, driving the economy and creating jobs. The Johor State Government continues to welcome high-impact businesses from around the world to ensure Johor remains the preferred location for quality investments.”